REGENERON PHARMACEUTICALS INC (REGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for REGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| REGN | Co-Chair of the Board; Board co-Chair, President and Chief Scientific Officer | 66 | ["Founding scientist of the Company","President and Chief Scientific Officer of the Company","11th most highly cited scientist in the world in the 1990s","Principal inventor and/or developer of 13 FDA-approved drugs","Founding scientist of the company","Co-Chair of the Board since 2023","M.D. and Ph.D. from Columbia University","Member of the National Academy of Sciences","Principal inventor/developer of 13 FDA-approved drugs"] | ["Technology Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Age: 66 Director since: 2001 Board co-Chair since: 2023 Board and Committee Membership 2025 Attendance Board of Directors: 15/15 Technology Committee: 2/2 Career Highlights Founding scientist of the Company; built and managed the Company since 1989 together with Dr. Schleifer President and Chief Scientific Officer of the Company Co Chair of the Board since 2023 and director of the Company since 2001 11th most highly cited scientist in the world in the 1990s Principal inventor and/or developer, together with key members of his team, of the 13 FDA approved drugs the Company has developed, EYLEA (aflibercept) Injection, EYLEA HD (aflibercept) 8 mg, Dupixent (dupilumab), Libtayo (cemiplimab), Praluent (alirocumab), Kevzara (sarilumab), Lynozyfic (linvoseltamab), Evkeeza (evinacumab dgnb), Inmazeb (atoltivimab, maftivimab and odesivimab ebgn), Veopoz (pozelimab) Injection, Otarmeni (lunsotogene parvec-cwha), ZALTRAP (ziv aflibercept) Injection for Intravenous Infusion, and ARCALYST (rilonacept) Injection for Subcutaneous Use, as well as of its foundation technologies, including the TRAP technology, VelociGene , and VelocImmune Experience and Expertise Industry Experience Executive/Leadership Experience Science/Biotech Background Research/Academic Experience Business Strategy/ Operations Experience Scientific Society Memberships The National Academy of Sciences Dr. Yancopoulos s significant industry and scientific experience and distinguished record of scientific expertise, as well as his extensive knowledge of the Company and in-depth knowledge of the Company s technologies and research and development programs, led the board to conclude that Dr. Yancopoulos should serve as a director.